Vincent O'Neill - Jan 20, 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Medical Officer
Signature
/s/ Richard I. Steinhart, as Attorney-in-Fact for Vincent O'Neill
Stock symbol
BTAI
Transactions as of
Jan 20, 2023
Transactions value $
-$879,208
Form type
4
Date filed
1/24/2023, 07:04 PM
Previous filing
Mar 16, 2022
Next filing
Jun 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Options Exercise $12.2K +29.7K $0.41* 29.7K Jan 20, 2023 Direct
transaction BTAI Common Stock Sale -$891K -29.7K -100% $30.00 0 Jan 20, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Employee Stock Option (right to buy) Options Exercise $0 -29.7K -50% $0.00 29.7K Jan 20, 2023 Common Stock 29.7K $0.41 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.
F2 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $30.00 to $30.05. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3 The options are fully vested and exercisable.